Many therapeutic monoclonal antibodies against COVID-19 neutralize SARS-CoV-2 infection by binding to the viral Spike glycoprotein and preventing the interaction between the SARS-CoV-2 and its entry receptor, angiotensin-converting enzyme 2 (ACE2) (40, 41). Here, ACE2 is linked to COVID-19.